Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma-Reference-Cited by-同舟云学术

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma

Published:2021-05-10 Issue:7 Volume:112 Page:2642-2651
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Liu Meijing¹,Deng Haobin¹,Mu Juan²^ORCID,Li Qing²,Pu Yedi²,Jiang Yili²,Deng Qi²,Qian Zhengzi³

Affiliation:

1. The First Central Clinical College of Tianjin Medical University Tianjin China

2. Department of Hematology Tianjin First Central Hospital School of Medicine Nankai University Tianjin China

3. Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin’s Clinical Research Center for Cancerthe Sino‐US Center for Lymphoma and Leukemia Research Tianjin China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14915

Reference41 articles.

1. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2. R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

3. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results

4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

5. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

2. Pretreatment with BTK inhibitors could improve the sensitivity of DLBCL cells to CAR-T cells in co-culture system by down-regulating the polarization of M2 macrophages;2024-04-19

3. CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC network;American Journal of Hematology;2024-04-08

4. Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data;Frontiers in Pharmacology;2024-01-24

5. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement;Leukemia & Lymphoma;2024-01-22